Literature DB >> 23339480

Dendrimer and cancer: a patent review (2006-present).

Xiaopan Cai1, Jingjing Hu, Jianru Xiao, Yiyun Cheng.   

Abstract

INTRODUCTION: Dendrimers were widely used in cancer diagnosis and therapy during the past decade. The surface functionalities allow bioactive molecules such as imaging probes, therapeutic compounds, targeting ligands to be present on dendrimer surface in a multivalent fashion. In addition, the interior pockets as well as the charged surface of dendrimer can be encapsulated/bound with anti-cancer drugs or therapeutic DNAs/siRNAs. AREAS COVERED: The combination of dendrimer chemistry and new cancer therapy techniques such as radiotherapy, photodynamic therapy, neuron capture therapy, and photothermal therapy provides promising strategies in future cancer therapy. Here, we focused on recent advances on this topic in the patents (2006 - present) and discussed the advantages of dendrimer technology in these inventions. EXPERT OPINION: The challenges and perspectives of dendrimer-based theranostics for cancer diagnosis and therapy are discussed. Future efforts in this area should be focused on designing materials to solve problems such as cancer metastasis, multidrug resistance (MDR) in cancer cells, and early-stage cancer diagnosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23339480     DOI: 10.1517/13543776.2013.761207

Source DB:  PubMed          Journal:  Expert Opin Ther Pat        ISSN: 1354-3776            Impact factor:   6.674


  3 in total

Review 1.  Nanotechnology in cancer therapy.

Authors:  Burcu Aslan; Bulent Ozpolat; Anil K Sood; Gabriel Lopez-Berestein
Journal:  J Drug Target       Date:  2013-09-30       Impact factor: 5.121

2.  In Vitro Studies of Polyhedral Oligo Silsesquioxanes: Evidence for Their Low Cytotoxicity.

Authors:  Anna Janaszewska; Kinga Gradzinska; Monika Marcinkowska; Barbara Klajnert-Maculewicz; Wlodzimierz A Stanczyk
Journal:  Materials (Basel)       Date:  2015-09-10       Impact factor: 3.623

3.  Synthesis and Evaluation of 177Lu-DOTA-DN(PTX)-BN for Selective and Concomitant Radio and Drug-Therapeutic Effect on Breast Cancer Cells.

Authors:  Brenda Gibbens-Bandala; Enrique Morales-Avila; Guillermina Ferro-Flores; Clara Santos-Cuevas; Myrna Luna-Gutiérrez; Gerardo Ramírez-Nava; Blanca Ocampo-García
Journal:  Polymers (Basel)       Date:  2019-09-27       Impact factor: 4.329

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.